The phase II SWOG S0800 trial evaluated the backbone neoadjuvant regimen of nab-paclitaxel 100 mg/m2 qw with dose-dense doxorubicin plus cyclophosphamide (AC) ± bevacizumab for the treatment of HER2-negative locally advanced or inflammatory breast cancer [14]. The gene discussed is ERBB2; the disease is inflammatory breast carcinoma.